Journalism in the Public Interest

The data on this website is limited and is from 2009 to 2013. For complete data from 2013 onward please see the newest version »
Payment Disclosure


Notable drugs produced by Boehringer Ingelheim include:

  • Spiriva (Bronchoplasm caused by emphysema, chronic bronchitis, or COPD)
  • Micardis (High blood pressure)
  • Pradaxa (Blood clots, reduces risk of stroke)
  • Combivent (COPD)
  • Atrovent (Chronic bronchitis, emphysema, asthma attacks)
  • Aggrenox (Prevents strokes in patients with blood flow disorders or blood clots)
  • Catapres (High blood pressure, ADHD)
  • Tradjenta (Type 2 diabetes)
  • Gilotrif (Metastatic non-small cell lung cancer)
  • Mirapex (Parkinson disease, restless legs syndrome)
  • Viramune (HIV)
  • Aptivus (HIV)

Important notes


Research payments are distinct from speaking and consulting. The figure listed does not reflect the actual compensation received by the physician listed as the principal investigator.

Payments for clinical studies may include costs associated with patient care, supplies, as well as the time spent by health care professionals treating patients and managing the study.

The reports include both the name of the health provider who performed the service and, when reported, the entity paid. They may be different.

Source: Boehringer Ingelheim. ProPublica last downloaded this record on Sept. 9, 2014.

I think this is my doctor — what should I do?

If your provider is listed, it’s because a drug company reported paying him or her for promotional activities, meals, travel, educational items, consulting or research. Such payments are legal, but research has shown that drug-company marketing can influence what a doctor prescribes. How you can use this data »